Targeting miR-5088-5p attenuates radioresistance by suppressing Slug.

Autor: Seok HJ; Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea., Choi JY; Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea., Yi JM; Department of Microbiology and Immunology, College of Medicine, Inje University, Busan, Republic of Korea., Bae IH; Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea.
Jazyk: angličtina
Zdroj: Non-coding RNA research [Noncoding RNA Res] 2023 Jan 02; Vol. 8 (2), pp. 164-173. Date of Electronic Publication: 2023 Jan 02 (Print Publication: 2023).
DOI: 10.1016/j.ncrna.2022.12.005
Abstrakt: Radiotherapy is widely used for cancer treatment, but paradoxically, it has been reported that surviving cancer cells can acquire resistance, leading to recurrence or metastasis. Efforts to reduce radioresistance are required to increase the effectiveness of radiotherapy. miRNAs are advantageous as therapeutic agents because it can simultaneously inhibit the expression of several target mRNAs. Therefore, this study discovered miRNA that regulated radioresistance and elucidated its signaling mechanism. Our previous study confirmed that miR-5088-5p was associated with malignancy and metastasis in breast cancer. As a study to clarify the relationship between radiation and miR-5088-5p identified as onco-miRNA, it was confirmed that radiation induced hypomethylation of the promoter of miR-5088-5p and its expression increased. On the other hand, miR-5088-5p inhibitors were confirmed to reduce radiation-induced epithelial-mesenchymal transition, stemness, and metastasis by reducing Slug. Therefore, this study showed the potential of miR-5088-5p inhibitors as therapeutic agents to suppress radioresistance.
Competing Interests: The authors declare no potential conflicts of interest.
(© 2023 The Authors.)
Databáze: MEDLINE